Fri.Nov 10, 2023

article thumbnail

FDA approves Takeda’s Adzynma for rare blood clotting disorder

Pharmaceutical Technology

The US FDA has granted approval for Takeda’s Adzynma for congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

article thumbnail

CAR-T biotech Cargo Therapeutics prices $281M IPO

Bio Pharma Dive

Cargo Therapeutics is the seventh oncology biotech to successfully price an IPO this year.

280
280
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca posts 16% drop in Q3 2023 profit after tax

Pharmaceutical Technology

AstraZeneca has posted a profit after tax of $1.37bn for Q3 2023 versus $1.64bn in the same quarter of the previous year, a decline of 16%.

246
246
article thumbnail

3 Considerations of the Patient Perspective from the 2023 Pain Therapeutics Summit

Worldwide Clinical Trials

Pain for chronic patients is not merely a condition they must manage but a social dynamic with various feelings and opinions. Its psychological impact is often understated, though it carries the same weight as pain’s physical effects. At this year’s annual Pain Therapeutics Summit , which took place in San Diego, CA, October 19 to 20th, I heard brilliant presentations on novel pain medication development, targeted discoveries, pain classifications, the NIH HEAL Initiative , trial designs, biomar

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Novo takes aim at obesity drug shortages with $6B manufacturing plan

Bio Pharma Dive

The maker of Wegovy and Ozempic plans to expand production in its home country of Denmark to help meet surging demand for the GLP-1 drugs.

article thumbnail

My Military Experience Was a Springboard to Career Success

Worldwide Clinical Trials

As someone who joined the military right after high school, I can say that it was one of the best decisions I ever made. My nearly perfect score on the Armed Services Vocational Aptitude Battery Test (ASVAB) qualified me for three positions, and I ended up taking the one that required a top-secret/SCI security clearance – as a Record Telecommunications Center Operator.

More Trending

article thumbnail

Valneva wins FDA approval for the first chikungunya vaccine

Pharmaceutical Technology

Following the three-month FDA review delay, Valneva’s live-attenuated chikungunya vaccine, Ixchiq received accelerated approval.

article thumbnail

100th patient joins ChariotMS trial for multiple sclerosis

Pharma Times

The trial is testing whether Mavenclad could benefit upper limb movement in MS patients - News - PharmaTimes

Trials 129
article thumbnail

Novartis’ urticaria drug meets all endpoints in Phase III trials

Pharmaceutical Technology

Novartis expects final Phase III REMIX trial readouts and regulatory submissions for remibrutinib in 2024.

Trials 147
article thumbnail

uMotif and Cogstate collaboration will include work on psychedelic trial

Outsourcing Pharma

A partnership between clinical research technology company uMotif and cognitive science company, Cogstate Limited, will see the companies continue existing work that includes a major phase 2 clinical trial of a psychedelic therapeutic.

Trials 97
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

EC approves Daiichi Sankyo’s Vanflyta for acute myeloid leukaemia

Pharmaceutical Technology

The EC has granted approval for Daiichi Sankyo’s Vanflyta to treat FLT3-ITD positive acute myeloid leukaemia (AML) in adults.

130
130
article thumbnail

SynaptixBio says NHS diagnostic service for rare diseases could be expanded

Pharma Times

A rare disease is defined as a condition that affects fewer than one in 2,000 people - News - PharmaTimes

118
118
article thumbnail

Bayer and Recursion expand oncology research partnership

Pharmaceutical Technology

Bayer has expanded a drug discovery research partnership with Recursion Pharmaceuticals in the precision oncology sector.

Research 130
article thumbnail

Phesi 'cracks the code' on validating sites' enrollment potential with patient access store

Outsourcing Pharma

Excessive costs cost and time to market in clinical trials could soon be eliminated thanks to the addition of a patient access store (PAS) to Phesi's trial accelerator platform.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Bristol Myers Squibb’s CAR-T Breyanzi wins FDA priority review  

Pharmaceutical Technology

If approved, Breyanzi would become the first and only CAR T cell therapy available for this specific patient population.

130
130
article thumbnail

Sosei Heptares and Kallyope collaboration milestone with first GPCR target

Outsourcing Pharma

The first scientific milestone stemming from a collaboration between Sosei Heptares and Kallyope that was announced last year (2022) has been reached.

article thumbnail

BIO-Europe 2023: Barriers remain in the AI pharma revolution

Pharmaceutical Technology

At the BIO-Europe conference, experts discussed remaining challenges in AI healthcare interventions.

130
130
article thumbnail

Valneva wins race, gaining FDA approval for chikungunya vaccine Ixchiq

Fierce Pharma

Valneva has won the race in the U.S. | The FDA has approved the world’s first chikungunya vaccine, giving a thumbs-up to Valneva’s Ixchiq. The French company receives a priority review voucher from the FDA, which it said it will sell. It is an accelerated approval and subject to a confirmatory, real-world study.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Eli Lilly reiterates POINT acquisition plans with tender offer extension

Pharmaceutical Technology

Amidst POINT’s shareholder turbulence, Lilly is keen to move forward with the $1.4bn acquisition.

130
130
article thumbnail

New tentative approval for Rising drug acetylcysteine

Drug Patent Watch

Acetylcysteine is the generic ingredient in seven branded drugs marketed by Cumberland Pharms, Aspen, Eugia Pharma, Exela Pharma, Fresenius Kabi Usa, Indoco, Rising, Sagent Pharms Inc, Steriscience, Zydus Pharms, Alvogen,… The post New tentative approval for Rising drug acetylcysteine appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 80
article thumbnail

Innovations Powering the Future of mRNA: What Biomanufacturers Need to Know

Pharmaceutical Technology

The advent of messenger RNA (mRNA) therapeutics has revolutionized modern medicines.

RNA 130
article thumbnail

Four Trends That Are Shaping the Future of Market Access

Drug Channels

Today’s guest post comes from James Pisano, Partner, Market Access at The Dedham Group and Dinesh Kabaleeswaran, SVP of Insights & Advisory Teams at MMIT. James and Dinesh offer four trends that they predict will shape medication access in the coming years. Click here to learn about consulting services from MMIT and its sister company The Dedham Group.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Bayer pledges up to $1.5bn for Recursion oncology alliance

pharmaphorum

Bayer pledges up to $1.5bn for Recursion oncology alliance Phil.

104
104
article thumbnail

Adzynma Wins FDA Approval as First Treatment for Ultra-Rare Blood Clotting Disorder cTTP

XTalks

The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals’ Adzynma, the first recombinant protein product for prophylactic (preventive) or on‑demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), an ultra-rare blood clotting disorder. Adzynma is administered intravenously once every other week for prophylactic ERT and once daily for on-demand ERT. cTTP is a very rare, inherited and life-threatening

article thumbnail

Novo Nordisk sets aside $6bn to boost production capacity

pharmaphorum

Novo Nordisk sets aside $6bn to boost production capacity Phil.

article thumbnail

EU regulator changes its mind on Mirati's KRAS inhibitor Krazati with a thumbs-up following initial snub

Fierce Pharma

Mirati Therapeutics’ KRAS inhibitor Krazati’s EU prospects weren’t looking good after an initial rejection from Europe's drugs regulator. | European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use (CHMP) snubbed the KRAS inhibitor in July, but changed its tune after a formal re-examination initiated by Mirati.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Takeda gets okay in US for rare blood disorder drug

pharmaphorum

Takeda gets okay in US for rare blood disorder drug Phil.

Drugs 101
article thumbnail

TraceLink Introduces Digital Recalls Solution

Pharmaceutical Commerce

New E2E workflow orchestration service is expected to simplify the processes of health systems and retail pharmacies while also reducing the risk of recalled items reaching patients.

article thumbnail

Molecular photoswitch improves visual acuity in retinitis pigmentosa

Drug Discovery World

Topline results from a Phase I/II clinical trial have shown that Kiora’s light-restoring small molecule KIO-301 has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP). The results of the ABACUS study for Kiora’s intravitreal (IVT) molecular photoswitch were presented at the American Academy of Ophthalmology annual conference by Russell Van Gelder, Professor and Chair, Department of Ophthalmology, University of Washington, School of Medicine.

article thumbnail

Creating patient-centric outreach materials for clinical trial patient recruitment [Antidote 2023 survey data]

Antidote

In 2018, we partnered with SCORR Marketing to conduct a survey aimed at gaining knowledge about the patient perception of clinical trial participation. We collected nearly 4,000 responses from individuals regarding what matters most to when considering a clinical trial.

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.